{"product_id":"jxr-fertility-marketing-mix","title":"Jinxin Fertility Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Jinxin Fertility’s product offerings, tiered pricing, clinic network, and targeted promotions combine to capture patient trust and market share—this brief preview highlights key strategies and competitive advantages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive ART Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Comprehensive ART Services at Jinxin Fertility cover the full spectrum of assisted reproductive technologies, including In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI), with clinic-reported live birth rates of 42% per IVF cycle for patients under 35 in 2025. Personalized protocols are designed by world-class embryologists, reducing cycle cancellation to under 4% and boosting cumulative pregnancy rates to 58% over three cycles. By end-2025 Jinxin integrated time-lapse incubation and AI-driven incubators, improving embryo selection accuracy by 18% and cutting lab costs per cycle by 7%. Pricing remains competitive: average IVF package price ¥48,000 in 2025, with financing options and outcome-based guarantees for select cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Genetic Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe group offers pre-implantation genetic testing (PGT) to detect chromosomal aneuploidies and single-gene disorders before embryo transfer, targeting patients with recurrent pregnancy loss or advanced maternal age; PGT increases live-birth rates by ~30% in women over 40 (2024 meta-analysis) and cuts miscarriage risk by ~50%. Internal lab capabilities deliver 24–48 hour turnaround and \u0026gt;99% analytic accuracy, lowering cycle cost-per-live-birth and improving clinic throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFertility Preservation Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJinxin Fertility’s egg and embryo freezing offers state-of-the-art vitrification cryopreservation with reported post-thaw survival rates above 90% (industry avg ~85% in 2024), targeting professionals delaying parenthood; average package price ¥28,000–¥45,000 in China (2024 clinics data) positions it as an affordable entry product for clients aged 25–35.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Maternal-Fetal Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrated Maternal-Fetal Care at Jinxin Fertility links fertility, gynecology, obstetrics, and pediatrics so patients get continuous care from consultation through childbirth and recovery, reducing care fragmentation.\u003c\/p\u003e\n\u003cp\u003eThis continuity boosted retention: clinic-reported data show a 22% higher repeat-service rate and a 14% rise in NPS in 2024 versus single-service peers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous care: fertility→birth→postnatal\u003c\/li\u003e\n\u003cli\u003eRetention +22% (2024 internal)\u003c\/li\u003e\n\u003cli\u003eNPS +14% vs peers (2024)\u003c\/li\u003e\n\u003cli\u003eImproved lifetime value via cross-service billing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHolistic Wellness and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJinxin Fertility bundles psychological counseling, nutritional plans, and traditional Chinese medicine (TCM) alongside IVF, aiming to lower stress and boost conception physiology; a 2024 internal audit reported 18% higher clinical pregnancy rates for patients using the full support package versus clinical-only care.\u003c\/p\u003e\n\u003cp\u003eThese services drive differentiation in a crowded market where 62% of Chinese IVF clinics offered only medical protocols in 2023, helping Jinxin charge a 12% premium on bundled care and lift ancillary revenue by 27% year-over-year in 2024.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\n\u003cli\u003e18% higher pregnancy rate with full package\u003c\/li\u003e\n\u003cli\u003e12% price premium on bundled care\u003c\/li\u003e\n\u003cli\u003e27% ancillary revenue growth in 2024\u003c\/li\u003e\n\u003cli\u003e62% of competitors offer clinical-only services (2023)\u003c\/li\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJinxin Fertility: 42% IVF live-births, 58% 3-cycle pregnancy, premium bundled care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJinxin Fertility offers end-to-end ART (IVF, IUI), PGT, vitrification, integrated maternal-fetal care, and complementary TCM\/psychological support, delivering clinic-reported 42% IVF live-births (\u0026lt;35, 2025), 58% cumulative pregnancy over 3 cycles, \u0026gt;90% post-thaw survival, 22% higher retention and 14% NPS lift (2024), with average IVF ¥48,000 and bundled premium +12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIVF live-birth rate (\u0026lt;35, 2025)\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative pregnancy (3 cycles)\u003c\/td\u003e\n\u003ctd\u003e58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-thaw survival (vitrification)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention uplift (2024)\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPS uplift vs peers (2024)\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg IVF price (2025)\u003c\/td\u003e\n\u003ctd\u003e¥48,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBundled-care premium\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Jinxin Fertility’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Jinxin Fertility’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotional priorities, and distribution channels to speed decision-making and alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlagship Chinese Medical Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJinxin Fertility runs high-capacity flagship hospitals in Chengdu and Shenzhen, each handling 8,000–12,000 cycles annually and contributing about 35% of group revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eThese centers feature advanced IVF labs, embryo vitrification, and PGT (preimplantation genetic testing), cutting average wait times to under 10 days in 2025, boosting conversion and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic US Network via HRC Fertility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough ownership of HRC Fertility, Jinxin operates a prestige US clinic network—12 locations as of 2025, concentrated in Southern California—letting the group access high-end US demand and bill premium IVF fees (avg US cycle \u0026gt; USD 20,000 in 2024). This axis enables cross-border care for international patients, drives tech transfer in embryo genetics and PGT, and sets a clinical benchmark that supports Jinxin's pricing and quality claims globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoutheast Asian Expansion in Laos\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Jinxin Laos facility serves as a regional hub offering assisted reproductive technology (ART) services that face stricter rules elsewhere; it handled ~1,200 cycles in 2024, drawing patients from Thailand, China, and Vietnam seeking treatments restricted at home.\u003c\/p\u003e\n\u003cp\u003ePositioned for cost-competitive care, the center meets ISO and JCI-style standards, cutting operational costs by ~28% vs. Bangkok clinics and pricing cycles ~30–40% lower, boosting cross-border revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telemedicine Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJinxin Fertility expanded reach via integrated digital platforms offering remote consultations, diagnostic tracking, and patient education, supporting 42% of first-touch patient interactions online in 2025.\u003c\/p\u003e\n\u003cp\u003eDigital footprint engages lower-tier cities (over 120 counties reached) where clinics lack presence, boosting lead conversion by 18% versus 2023.\u003c\/p\u003e\n\u003cp\u003eTelemedicine streamlines preliminary treatment—virtual triage cuts in-person visits by 37% and raised appointment completion among working professionals to 81%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e42% first-touch online (2025)\u003c\/li\u003e\n\u003cli\u003e120+ counties reached\u003c\/li\u003e\n\u003cli\u003e18% higher lead conversion\u003c\/li\u003e\n\u003cli\u003e37% fewer in-person prelim visits\u003c\/li\u003e\n\u003cli\u003e81% appointment completion for professionals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Referral and Partner Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJinxin Fertility channels patients via a regional network of partner clinics and 1,200+ referral physicians across 12 provinces, steering cases to its specialized surgical centers to boost case volume without heavy capex.\u003c\/p\u003e\n\u003cp\u003ePartners receive standardized training and shared diagnostics, lifting preliminary-care quality—internal data show a 22% higher referral-to-treatment conversion after training programs started in 2024.\u003c\/p\u003e\n\u003cp\u003eDecentralized distribution grows brand reach and revenue: referrals contributed an estimated CNY 420 million (≈USD 61m) in 2025 revenue, avoiding costs of building full hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,200+ referral doctors\u003c\/li\u003e\n\u003cli\u003e12 provinces covered\u003c\/li\u003e\n\u003cli\u003e22% conversion lift post-training\u003c\/li\u003e\n\u003cli\u003eCNY 420M revenue from referrals (2025 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJinxin blends flagship hospitals, HRC US, Laos hub, digital \u0026amp; referrals to drive 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJinxin’s place strategy mixes flagship hospitals (Chengdu, Shenzhen: 8–12k cycles, ~35% 2024 revenue), HRC US network (12 clinics, avg US cycle \u0026gt;USD20k in 2024), Laos hub (~1,200 cycles 2024, 30–40% lower pricing), digital channels (42% first-touch 2025) and 1,200+ referral doctors (CNY420M revenue est. 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlagship cycles\u003c\/td\u003e\n\u003ctd\u003e8–12k each\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlagship rev%\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHRC locations\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaos cycles\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital first-touch\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferral revenue\u003c\/td\u003e\n\u003ctd\u003eCNY420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eJinxin Fertility 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Jinxin Fertility 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same ready-made, editable document you'll download immediately after checkout, fully complete and ready to use for strategy or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749899710841,"sku":"jxr-fertility-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jxr-fertility-marketing-mix.png?v=1772220002","url":"https:\/\/growthsharematrix.com\/products\/jxr-fertility-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}